Director John L. Higgins filed a Form 4 with the SEC on November 2, 2026, reporting the acquisition of 2,750 shares of Bio-Techne Corp common stock on October 29, 2026, along with a new stock option grant covering 3,777 shares.

Key Highlights

  • Shares acquired: John L. Higgins acquired 2,750 shares of Bio-Techne Corp common stock on October 29, 2026, at a price of $0, recorded as transaction code "A" (acquired).
  • Post-transaction holdings: Following the transaction, Higgins directly beneficially owned 80,004 shares of common stock, according to the filing.
  • New option grant: A stock option (right to buy) covering 3,777 shares of common stock was reported, with an exercise price of $60.96, exercisable from October 29, 2026, and expiring October 30, 2035.
  • Total options held: The filing lists nine stock option grants held directly by Higgins, with exercise prices ranging from $31.26 to $128.81 and covering a total of 51,381 underlying shares of common stock.
  • Reporting person's role: Higgins is identified as a Director of Bio-Techne Corp (NASDAQ:TECH) in the filing.
  • Filing agent: The form was signed by Andrew Nick as Attorney-in-Fact for John L. Higgins pursuant to a previously filed Power of Attorney.

Director Higgins Reports October 2026 Share Award and Option Grant at Bio-Techne

According to the Form 4 filed on November 2, 2026, John L. Higgins, a Director of Bio-Techne Corp, acquired 2,750 shares of the company's common stock on October 29, 2026. The filing records the price for this acquisition as $0, and transaction code "A" indicates the shares were acquired rather than disposed of. Following this transaction, Higgins held 80,004 shares of Bio-Techne common stock directly.

In addition to the common stock acquisition, the filing reports a new stock option grant. The option covers 3,777 shares of common stock with an exercise price of $60.96 per share. According to the filing, the option became exercisable on October 29, 2026, and is set to expire on October 30, 2035. The filing lists eight previously reported stock option grants also held directly by Higgins, with exercise prices of $31.26, $44.96, $50.41, $63.92, $128.81, $73.94, $61.51, and $68.37, covering 12,500, 7,592, 8,044, 6,028, 2,532, 3,460, 3,937, and 3,511 shares of common stock, respectively.

The Form 4 was signed by Andrew Nick as Attorney-in-Fact for John L. Higgins pursuant to a Power of Attorney previously filed. All reported securities are held in direct ownership form, as indicated in the filing.

What Was Disclosed

Director John L. Higgins disclosed the acquisition of 2,750 Bio-Techne common shares at $0 on October 29, 2026, bringing his direct holdings to 80,004 shares, along with a new stock option grant for 3,777 shares at an exercise price of $60.96.